Octapharma is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved an updated Prescribing Information (PI) for NUWIQ®, Octapharma’s human cell line-derived recombinant factor VIII (FVIII). NUWIQ ® is approved for the prevention and treatment of bleeding in people with haemophilia A. 

Octapharma announces FDA approval of updated NUWIQ® Prescribing Information to include immunogenicity data in previously untreated patients

Dina Dickson CRM Project Manager, Octapharma USA

Thomas Stork Sales Manager, Octapharma Germany

Michele Noll Research Associate Quality Control/ Qualified Person, Octapharma Biopharmaceuticals, Germany

Alma Torokoff Pharmaceutical Technician, Biopharmaceutical Production, Octapharma Sweden

Andra Jones Senior Director, Operations, Octapharma Plasma, Inc.

At Octapharma, we foster a culture that brings out the best in our people to fulfil our purpose of providing new health solutions advancing human life. We believe we can drive innovation, performance and reputation – and enhance our people’s work experience – through our culture. 

Building on strong values 

Annual Report 2021

Building on strong values

Celebrating our milestones 

It all started in 1983 with a single idea: people with haemophilia deserve access to better products. Today we help thousands of patients worldwide.  

Celebrating our milestones

85% of the plasma used to manufacture Octapharma products is sourced from company-owned donation centres.

More than 80% of the plasma used to manufacture Octapharma products is sourced from company-owned donation centres. 

Earning donors’ trust

The company’s objective is to increase manufacturing output by 15% in 2022.

Laurent Contet Operational Excellence Manager Lingolsheim, France

Julien Correia Head of Fractionation Lingolsheim, France

In 2021, Octapharma launched a number of production improvement initiatives to transform our manufacturing capabilities and boost capacity. 

Securing our future by boosting capacity

Measures to counter COVID-19 severely affected the availability of blood products around the world and forced many healthcare facilities to cancel elective surgical procedures and restrict non-essential care. 

The essential role of PBM during the pandemic 

Update of Summary of Product Characteristics for Nuwiq® 

Update of Summary of Product Characteristics for Nuwiq® includes data on effective bleed protection with twice-weekly dosing with personalised prophylaxis

Positive results for fibryga published in the Journal of Thrombosis and Haemostasis

The final results of the Phase 3 clinical trial investigating fibryga® for the treatment of bleeding and surgical prophylaxis in patients with congenital fibrinogen deficiency (FORMA-02) has been published in the Journal of Thrombosis and Haemostasis (JTH).  FORMA-02

Positive results for fibryga, fibrinogen deficiency, Journal of Thrombosis and Haemostasis. FORMA-02

Positive results for fibryga® in the treatment of bleeding and surgical prophylaxis in patients with congenital fibrinogen deficiency (FORMA-02) published in the Journal of Thrombosis and Haemostasis

From childhood dream to research team

Andrea is Team Leader for Plasma R&D in Vienna.

Andrea and her team’s latest challenges focus on designing two new developments for our pooled plasma products.

Final results from the NuProtect study demonstrating efficacy of Nuwiq

Final results from the NuProtect study demonstrating efficacy of Nuwiq® in PUPs

Final results from the NuProtect study demonstrating efficacy of Nuwiq® (simoctocog alfa) in previously untreated patients (PUPs) presented at ASH 2019

Persistence - and ingenuity - pays off

Christoph and his team relish a challenge.

Octapharma Group reports strong results for 2018

ommenting on the Group’s results, Octapharma CEO and Chairman Wolfgang Marguerre said: “In 2018, we continued to drive growth in many of our products."

Timely help for critically ill patients

Octapharma Group publishes 2017 annual results

Over the last six years, the Octapharma Group has accomplished a remarkable compound annual growth rate of 15% and reports another record-breaking result for 2017.

Octapharma Group publishes 2017 annual results reporting revenue of €1.72 billion and operating income of €349 million

Additional resources

Octapharma is committed to improving awareness of bleeding disorders, which in turn helps more patients like Andrew, through support of a number of different initiatives. Watch his story to learn more and visit the tool www.vwdtest.com.

Take one day at a time and live 

Low inhibitor rate with octanate® in previously untreated patients

Octapharma is delighted to announce the publication of final data from a Good Clinical Practice (GCP) trial in PUPs in the internationally renowned medical journal Haemophilia.

Low inhibitor rate with octanate®

Low inhibitor rate with octanate® in previously untreated patients (PUPs) with severe haemophilia A

Medicine as an art form

Ruth Wagner, Group Manager R&D Cell Line Development at Octapharma

Ruth is Group Manager R&D Cell Line Development at the Octapharma Biopharmaceuticals centre in Heidelberg.

Having the right balance of different talents in a team is a key contributing factor to innovation.

Final results from the NuProtect study

Highlighting the NuProtect study at ASH 2019

Octapharma announces the presentation of the final results from the NuProtect study of Nuwiq® (simoctocog alfa) in previously untreated patients (PUPs) at ASH 2019

Octapharma share promising preclinical data for SubQ-8

Octapharma announced today that pre-clinical data for SubQ-8 were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, UK.

Octapharma share promising preclinical data for SubQ-8, a novel subcutaneous recombinant FVIII, at WFH 2018

Octapharma Group publishes 2016 annual results 

The Octapharma Group can report a record-breaking result with sales of €1.6 billion, which represents an increase of €87 million or 5.8% compared with 2015.

Octapharma Group publishes 2016 annual results

Octapharma Group publishes 2016 annual results reporting revenue of €1.6 billion and operating income of €383 million

New Data on Haemophilia A or von Willebrand Disease at ISTH 2019

Octapharma to Present New Data on Management of People with Haemophilia A or von Willebrand Disease at ISTH 2019

A groundbreaking Canadian study, "PROXY," published in The Journal of Thrombosis and Haemostasis (JTH), offers new hope for patients on oral factor Xa (FXa) inhibitors facing emergency surgery. 

Une étude canadienne a révélé une nouvelle approche pour gérer les risques hémorragiques chez les patients sous inhibiteurs du FXa, en utilisant l’octaplex® en prophylaxie lors de chirurgies d’urgence

Une étude canadienne révèle une nouvelle approche pour gérer les risques hémorragiques chez les patients sous inhibiteurs du FXa en utilisant l’octaplex® en prophylaxie lors de chirurgies d’urgence

Canadian Study Explores Preoperative 4F-PCC for Managing Bleeding Risks in AF Patients on FXa Inhibitors

Octapharma Canada is pleased to announce the Canadian approval of Wilate® (von Willebrand Factor/Coagulation Factor VIII Complex (Human) for use in prophylaxis treatment of Von Willebrand Disease (VWD) in adults and pediatric patients aged 6 and older with any type of VWD.

Wilate® is now approved in Canada for Prophylaxis in Von Willebrand Disease

Approval Brings Prophylaxis Benefits to VWD Patients, Aligning Treatment Standards with Hemophilia A Care

Wilate® is now approved in Canada for Prophylaxis in Von Willebrand Disease 

Wilate® is now approved in Canada for Prophylaxis in Von Willebrand Disease, 

Akron Biotech Signs Exclusive Global Agreement with Octapharma to Produce Virally Inactivated Human AB Serum derived from Octaplas® for the Cell Therapy Market

Akron Biotech signs exclusive global agreement with Octapharma

Partnership aims to enhance safety of human serum from viruses  such as the virus that causes COVID-19

Akron Biotech signs exclusive global agreement with Octapharma to produce virally inactivated human AB serum derived from Octaplas® for the cell therapy market

Akron Biotech Signs Exclusive Global Agreement with Octapharma 

From Toila in Estonia, both boys were diagnosed with the rare immune disease X-linked agammaglobulinemia (XLA), which means they lack the antibodies needed to defend their bodies against infection. 

Winners never quit, quitters never win 

Winners never quit

Octapharma to build new multi-use venue

Octapharma to invest Euro 21 million to build a new multi-use venue in Springe, Germany. Octapharma has confirmed to invest Euro 21 million to build a new multi-function facility in Springe, Germany

Octapharma has confirmed to invest Euro 21 million to build a new multi-function facility in Springe, Germany.

Octapharma to invest Euro 21 million to build a new multi-use venue in Springe, Germany

update on the development of SubQ-8 ISTH 2019

Octapharma communicates an update on the development of SubQ-8, a novel subcutaneous recombinant FVIII, at ISTH 2019

Octapharma present new data on the benefits of Nuwiq®

Octapharma announced today that new data on the benefits of Nuwiq® in patients with haemophilia A were presented during a symposium at the recent World Federation of Hemophilia (WFH) 2018 World Congress in Glasgow, UK.

Octapharma present new data on the benefits of Nuwiq® in patients with haemophilia A at the World Federation of Hemophilia 2018 World Congress

Octapharma activities prominent at the upcoming 2017 ISTH Congress

Octapharma today announced that it will be actively involved in a wide range of activities at this year’s International Society on Thrombosis and Haemostasis (ISTH) Congress. The Congress will be held in Berlin, Germany from 8–13 July. Octapharma is delighted to be a Platinum Sponsor of the Congress.

Octapharma activities prominent at 2017 ISTH Congress

Octapharma activities prominent at the upcoming 2017 ISTH Congress in Berlin, Germany

Octapharma’s fibryga® receives European label extension to treat acquired fibrinogen deficiency (AFD) 

Fibryga® receives European label extension to treat acquired fibrinogen deficiency (AFD) 

Using big data to improve lives

Angelika and her team monitor all information from the donor centre to manufacturing.

The ability to collect and access vast data sets of plasma donations is the foundation of the team.

Octapharma Canada a le plaisir d’annoncer que l’Institut national d’excellence en santé et en services sociaux (INESSS) a recommandé l’ajout de FibrygaMC (concentré de fibrinogène humain) pour utilisation dans la déficience en fibrinogène (AFD) à la liste des produits du système du sang dans la province de Québec. 

L’INESSS recommande l’ajout de FibrygaMC à la liste des produits du système du sang du Québec

L’INESSS recommande l’ajout de Fibryga (MC) à la liste des produits du système du sang du Québec

INESSS recommends the addition of Fibryga® to the blood product list of Québec

Kellie Jo has dedicated many hours to conducting her own research on dermatomyositis.

The average time for diagnosis of a serious autoimmune disease in the USA is 4.6 years, during which time patients typically see an average of 4.8 doctors, according to the American Autoimmune Related Diseases Association (AARDA)T

Pushing through the pain: The long road to a dermatomyositis diagnosis

Debbie has tried all sorts of treatments, but today she uses Octapharma’s von Willebrand/ coagulation factor VIII concentrate.

Wearing her bruises with pride: Living with von Willebrand disease

Wearing her bruises with pride: living with von Willebrand disease 

Implementation of a Patient Blood Management (PBM) strategy played a pivotal role in life-changing surgery to separate conjoined Haitian twin girls at the Exequiel Gonzalez Cortés Hospital in Santiago, Chile in October 2021 – during the peak of the COVID-19 pandemic in the country. 

PBM and use of factor concentrates are key to successful separation of conjoined twins 

Based in Vienna, Irene Beckmann played an instrumental role in the ProDERM study.

Towards the successful treatment of dermatomyositis 

Octapharma to demonstrate ongoing commitment to improving the long-term health of people with haemophilia A at the 14th EAHAD annual congress 

Octapharma to demonstrate ongoing commitment at the 14th EAHAD annual congress 

Engaging with patients

New data ISTH 2019 

Octapharma presents new data on the benefits of Nuwiq® in patients with haemophilia A at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Cong

Octapharma presents new data on the benefits of Nuwiq® in patients with haemophilia A at the International Society on Thrombosis and Haemostasis (ISTH) 2019 Congress

Octapharma announces approval of new Nuwiq® product strengths

Octapharma announced today that the European Medicines Agency (EMA) has approved an extension of marketing authorisation for its human cell line-derived recombinant factor VIII (rFVIII) product, Nuwiq®.

Octapharma announces approval of new Nuwiq® product strengths in Europe

Press Release

Octapharma announces approval of new Nuwiq® product strengths in Europe, increasing dosing flexibility for patients with haemophilia A

Octapharma announces publication of data on fibryga

Octapharma announces publication of data on fibryga® for the treatment of acquired fibrinogen deficiency in patients undergoing cardiac surgery

New data on fibryga® for the treatment of acquired fibrinogen deficiency in patients undergoing cardiac surgery

Octapharma symposium at ISTH Berlin

Octapharma is pleased to announce the success of yesterday’s symposium at the International Society on Thrombosis and Haemostasis (ISTH) congress held in Berlin, Germany.

Octapharma symposium at ISTH Berlin supports progress in lifelong treatment of high-risk patients with von Willebrand disease (VWD) and haemophilia A

An eye for detail

 Octaplas LG® Powder for solution for infusion: Making a Vital Contribution to the Health of Canadian Soldiers

Octaplas LG® Poudre pour solution pour perfusion : apporter une contribution vitale à la santé des soldats canadiens

Octaplas LG® Powder for solution for infusion: Making a Vital Contribution to the Health of Canadian Soldiers

Patient Blood Management (PBM) is a multidisciplinary, evidence-based approach to individualising patient care. 

Patient Blood Management – A new standard of care

Annual Report 2020

William, who first donated two years ago after getting the idea from his brother-in-law, now gives plasma twice a week.

At a glance

Octapharma donor centres introduced stringent new safety measures to prevent COVID-19 pandemic, including the wearing of masks, increased sanitation and social distancing. 

Donating plasma and saving lives  

Symptoms of VWD

Friendly and easy-going, Kerri continues to manage everything with her characteristic optimism.

Treating VWD

When Kerri first heard about COVID-19, she didn’t immediately grasp the severity of the disease or how big an impact it would have on all our daily lives. But she quickly realised the possible implications for patients like herself. 

Facing VWD during COVID-19 as both a nurse and patient

Study Suggests that Intravenous Immunoglobulin (IVIG) Increases Survival in Critically Ill COVID-19 Patients requiring Intubation with Mechanical Ventilation

Octapharma Reports Positive Data from Octagam Usage in Critically Ill COVID-19 Patients

Octapharma Reports Positive Data from octagam® Usage in Critically Ill COVID-19 Patients

Fibrinogen, a protein necessary for clot formation, is the first factor to become deficient during perioperative bleeding and is often the only deficiency that needs to be treated. Learn more on how doctors use fibrinogen concentrate.

Patient Blood Management 

Blood is essential for the wellbeing of everyone.

Blood is essential for the wellbeing of everyone

Octapharma USA today sponsored the patient symposium “Hope Ignites: Stories to Inspire,” during the Hemophilia Federation of America (HFA) Annual Symposium in Providence, Rhode Island.

Octapharma USA Sponsors ‘Hope Ignites: Stories to Inspire’

Octapharma USA Sponsors ‘Hope Ignites: Stories to Inspire’ Program at Hemophilia Federation of America Annual Symposium

Bringing new optimal therapies to patients in need

Bringing new optimal therapies

Rute Martins, Customer Service Manager at Corporate Customer Service

Rute and her team handle all the orders for finished products and other enquiries coming from 115 countries around the globe.

Getting our medicines to patients

Octapharma is playing a prominent role this week at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Berlin, Germany. As a platinum sponsor of the congress, Octapharma’s active involvement includes two sponsored scientific symposia.

ISTH 2017, Berlin: Octapharma presents exciting Nuwiq® 

ISTH 2017, Berlin: Octapharma presents exciting Nuwiq® data in previously untreated patients and demonstrates real-life value of personalised prophylaxis for Haemophilia A

ISTH 2017, Berlin: Octapharma presents exciting Nuwiq® data

Real hope for Brandon

Fibryga® receives Swissmedic approval

Octapharma receives Swissmedic approval for fibryga® to treat congenital and acquired fibrinogen deficiencies

Octapharma receives Swissmedic approval for fibryga®

Letter from the Chief Financial Officer, Roger Mächler - Annual Report 2020

Delivering strong performance in 2020

CLL explained

“I am so lucky to have found myself surrounded by such support,” says Ingrid.

Treatment

In March 2003, Ingrid was diagnosed with Chronic Lymphocytic Leukaemia. “What was meant to be a reassuring check-up with my doctor turned my life upside down,” she remembers. 

Cancer was not part of the plan

New data to be presented at the ISTH 2020 Virtual Congress demonstrating Octapharma’s commitment to patients with bleeding disorders

ISTH2020 results

 Technician, operator and shift leader discussing the next packaging steps.

Semi-automatic visual inspection using a magnifying glass.

Inspecting finished products with intense concentration

Inspecting finished products

Octapharma announced today the launch of the Canadian PREVAIL (Immune Tolerance Induction in Hemophilia A Patients using wilate®) study for patients with Hemophilia A.

New Canadian study to improve eradication of inhibitors in Hemophilia A patients

New Canadian study to improve eradication of inhibitors

Octapharma announces positive new clinical data in 66 previously treated patients (PTPs) with severe haemophilia A (HA) undergoing PK-guided personalized prophylaxis with Nuwiq® according to the NuPreviq Approach. Data from the NuPreviq study (GENA-21, NCT01863758) were published online in April 2017.

Octapharma underlines strong commitment to haemophilia A patients

Octapharma underlines strong commitment to haemophilia A patients with the publication of new clinical data on PK-guided personalized prophylaxis according to the NuPreviq Approach with Nuwiq®

Octapharma USA sponsored the National Hemophilia Foundation’s 69th Annual Meeting in Chicago and provided a patient symposium sharing the inspirational stories of three young men with bleeding disorders, including Chris Bombardier.

Octapharma USA Sponsors NHF Annual Meeting

Octapharma USA Sponsors NHF Annual Meeting, Shares Inspirational Bleeding Disorders Community Achievements

Strong commitment for the two brothers from Estonia

Centre management collaborate to ensure quality and traceability of plasma collected.

Our valued donors provide life-saving plasma for the medicines we create.

Actualités et témoignages

À propos de nous

Plasma

Thérapies

Travailler avec nous

Actualités